Forschung

Direkt zum Inhalt | Direkt zur Navigation

Benutzerspezifische Werkzeuge

Sektionen
AG Hamprecht
Sie sind hier: Startseite / Forschung / AG Hamprecht

AG Hamprecht

Group Leader: Priv.-Doz. Dr. med. Axel Hamprecht
Phone: +49 221 478 32017 [Email protection active, please enable JavaScript.]

Co-workers:
Katharina Füßl
Florian Koroska
Esther Leidig
Ahmad  Saleh
Dr. rer. nat. Thorsten Wille


Research Topic:

Resistance mechanisms in gram-negative bacteria

Resistance to antibiotics has dramatically increased in recent years, especially among gram-negative bacteria (e.g., Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa). These bacteria cause life threatening infections (e.g. sepsis, pneumonia) and can be transmitted from patient to patient.

In the last years, we witness an increasing resistance to commonly used beta-lactam antibiotics, especially to extended spectrum cephalosporins. Resistance is commonly caused by extended spectrum beta lactamases that can hydrolyze many beta lactams.

Another threat which is still rare in Germany is the resistance to carbapenems (e.g., ertapenem, meropenem, imipenem), which is caused by carbapenemases such as NDM (New Delhi metallo-beta-lactamase), KPC, VIM, OXA-48 and others.

The main interest of our group is to identify and characterize resistant Gram-negative bacteria and to understand why some species and clones can disseminate successfully.

 

azole-resistant-aspergillus-fumigatus.jpg

Azole-resistant Aspergillus fumigatus (TR46/Y121F/T289A mutation)

Detection and resistance of medically important fungi

With the growing number of immune-compromised patients, we see an increasing number of infections by opportunistic pathogens, especially fungi. Invasive fungal infections such as aspergillosis show a very high mortality and are particularly difficult to treat. This problem has been aggravated by an increasing resistance to triazole antifungals, the mainstay of aspergillosis therapy. This phenomenon has only been observed in the last years and is likely caused the use of azole fungicides in agriculture.

Our current research focuses on azole resistance in Aspergillus spp. and the detection and resistance of “rare” fungi, such as Fusarium spp.


Brief description in German

Unsere Arbeitsgruppe beschäftigt sich mit Resistenzen und Resistenzmechanismen von gram-negativen Bakterien und medizinisch wichtigen Pilzen.

Resistenzen gegenüber Antibiotika und Antimykotika haben in den letzten Jahren dramatisch zugenommen. Dies ist u.a. bedingt durch den zu häufigen Einsatz von Antibiotika (Klinik, ambulant, Tierhaltung) und von Antimykotika (Landwirtschaft).

Unsere Arbeitsgruppe hat sich zum Ziel gesetzt, resistente Stämme nachzuweisen und zu charakterisieren sowie die zugrundeliegenden Resistenzmechanismen aufzuklären. Unser Hauptinteresse liegt hierbei bei Antibiotikaresistenzen gegenüber Betalaktamen (z.B. durch ESBLs oder Carbapenemasen wie NDM, KPC, OXA-48 u.a.) und Antimykotikaresistenzen bei Aspergillus spp. gegenüber Triazolen.

 

Selected publications

Gutiérrez-Gutiérrez B, Bonomo RA, Carmeli Y, Paterson DL, Almirante B, Martínez-Martínez L, Oliver A, Calbo E, Peña C, Akova M, Pitout J, Origüen J, Pintado V, García-Vázquez E, Gasch O, Hamprecht A, Prim N, Tumbarello M, Bou G, Viale P, Tacconelli E, Almela M, Pérez F, Giamarellou H, Cisneros JM, Schwaber MJ, Venditti M, Lowman W, Bermejo J, Hsueh PR, Mora-Rillo M, Gracia-Ahulfinger I, Pascual A, Rodríguez-Baño J; REIPI/ESGBIS/INCREMENT Group. Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study. J Antimicrob Chemother. 2016 Feb 22 [Epub ahead of print]

Jazmati N, Hein R, Hamprecht A. Use of an enrichment broth improves the detection of ESBL producing Enterobacteriaceae in clinical stool samples. J Clin Microbiol. 2016 Feb;54(2):467-70

Bacher P, Jochheim-Richter A, Mockel-Tenbrink N, Kniemeyer O, Wingenfeld E, Alex R, Ortigao A, Karpova D, Lehrnbecher T, Ullmann AJ, Hamprecht A, Cornely O, Brakhage AA, Assenmacher M, Bonig H, Scheffold A. Clinical-scale isolation of the total Aspergillus fumigatus-reactive T-helper cell repertoire for adoptive transfer. Cytotherapy 2015 Oct;17(10):1396-405

Ahmed S, Khan Z, Wang X-w, Moussa TA, Al-Zahrani H, Almaghrabi O, Sutton D, Ahmad S, Groenewald J, Alastruey-Izquierdo A, van Diepeningen A, Menken SBJ, Najafzadeh MJ, Crous P, Cornely O, Hamprecht A, Vehreschild MGT, Kindo AJ, de Hoog GS. Chaetomium-like fungi causing opportunistic infections in humans: a possible role for extremotolerance. Fungal Diversity 2015: 1-16

Liss B, Vehreschild JJ, Bangard C, Maintz D, Frank K, Grönke S, Michels G, Hamprecht A, Wisplinghoff H, Markiefka B, Hekmat K, Vehreschild MJ, Cornely OA. Our 2015 approach to invasive pulmonary aspergillosis. Mycoses 2015 Jun;58(6):375-82

Steinmann J, Hamprecht A, Vehreschild MJ, Cornely OA, Buchheidt D, Spiess B, Koldehoff M, Buer J, Meis JF, Rath PM. Emergence of azole-resistant invasive aspergillosis in HSCT recipients in Germany. J Antimicrob Chemother 2015 May;70(5):1522-6

Gruber TM, Göttig S, Mark L, Christ S, Kempf VA, Wichelhaus TA, Hamprecht A. Pathogenicity of pan-drug-resistant Serratia marcescens harbouring blaNDM-1. J Antimicrob Chemother 2015 Apr;70(4):1026-30

Bacher P, Steinbach A, Kniemeyer O, Hamprecht A, Assenmacher M, Vehreschild MJ, Vehreschild JJ, Brakhage AA, Cornely OA, Scheffold A. Fungus-Specific CD4(+) T Cells for Rapid Identification of Invasive Pulmonary Mold Infection. Am J Respir Crit Care Med. 2015 Feb 1;191(3):348-52

Gruber TM, Göttig S, Mark L, Christ S, Kempf VA, Wichelhaus TA and Hamprecht A.
Pathogenicity of pan-drug-resistant Serratia marcescens harbouring blaNDM-1. J
Antimicrob Chemother 2014 Dec 2

Hamprecht A and Göttig S. Treatment of Infections Caused by Carbapenem-Resistant Enterobacteriaceae. Curr Treat Options Infect Dis Aug 2014, DOI 10.1007/s40506-014-0029-x

Vehreschild MJ, Hamprecht A, Peterson L, Schubert S, Häntschel M, Peter S, Schafhausen P, Rohde H, Lilienfeld-Toal MV, Bekeredjian-Ding I, Libam J, Hellmich M, Vehreschild JJ, Cornely OA, Seifert H. A multicentre cohort study on colonization and infection with ESBL-producing Enterobacteriaceae in high-risk patients with haematological malignancies. J Antimicrob Chemother. 2014 Aug 6.

Spiess B, Postina P, Reinwald M, Cornely OA, Hamprecht A, Hoenigl M, Lass-Flörl C, Rath PM, Steinmann J, Miethke T, Lauten M, Will S, Merker N, Hofmann WK, Buchheidt D. Incidence of Cyp51 A Key Mutations in Aspergillus fumigatus-A Study on Primary Clinical Samples of Immunocompromised Patients in the Period of 1995-2013. PLoS One. 2014 Jul 29;9(7):e103113

Maschmeyer G, Carratalà J, Buchheidt D, Hamprecht A, Heussel CP, Kahl C, Lorenz J, Neumann S, Rieger C, Ruhnke M, Salwender H, Schmidt-Hieber M, Azoulay E. Diagnosis and Antimicrobial Therapy of Lung Infiltrates in Febrile Neutropenic Patients (allogeneic SCT excluded) Updated Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Oncol. 2014 May 15.

Fischer J, van Koningsbruggen-Rietschel S, Rietschel E, Vehreschild MJ, Wisplinghoff H, Krönke M, Hamprecht A. Prevalence and molecular characterization of azole resistance in Aspergillus spp. isolates from German cystic fibrosis patients. J Antimicrob Chemother. 2014 Jun;69(6):1533-6.

Hamprecht A, Christ S, Oestreicher T, Plum G, Kempf VA, Göttig S. Performance of two MALDI-TOF MS systems for the identification of yeasts isolated from bloodstream infections and cerebrospinal fluids using a time-saving direct transfer protocol. Med Microbiol Immunol 2014 Apr;203(2):93-9

Göttig S, Hamprecht AG, Christ S, Kempf VA, Wichelhaus TA. Detection of NDM-7  in Germany, a new variant of the New Delhi metallo-β-lactamase with increased carbapenemase activity. J Antimicrob Chemother 2013 Aug;68(8):1737-40

Schemuth H, Dittmer S, Lackner M, Sedlacek L, Hamprecht A, Steinmann E, Buer  J, Rath PM, Steinmann J. In vitro activity of colistin as single agent and in combination with antifungals against filamentous fungi occurring in patients with cystic fibrosis. Mycoses 2013 May;56(3):297-303

Hamprecht A, Poirel L, Göttig S, Seifert H, Kaase M, Nordmann P. Detection of the carbapenemase GIM-1 in Enterobacter cloacae in Germany. J Antimicrob Chemother 2013 Mar;68(3):558-61

Hamprecht, A., D. Buchheidt, J. Vehreschild, O. Cornely, B. Spiess, G. Plum, T. Halbsguth, N. Kutsch, D. Stippel, P. Kahl, T. Persigehl, A. Steinbach, B. Bos, M. Hallek, und M. Vehreschild. Azole-resistant invasive aspergillosis in a patient with acute myeloid leukaemia in Germany. Euro Surveill 2012 Sep 6;17(36):20262.

Higgins PG, Schneiders T, Hamprecht A, Seifert H. In Vivo Selection of a Missense Mutation in adeR and Conversion of the Novel blaOXA-164 into blaOXA-58 in Carbapenem-Resistant Acinetobacter baumannii Isolated From a Hospitalized Patient, Antimicrob Agents Chemother 2010 Oct 4

 

 

Offene Stellen
Offene Stellen sind unter der Rubrik „Stellen“ auf der Homepage des IMMIH aufgeführt.
Für Projekte im Rahmen von Master- oder Diplomarbeiten suchen wir immer engagierte und hoch motivierte Studenten. Für diese und andere Anfragen wenden Sie sich bitte direkt an den Gruppenleiter.